Condition: Platinum-resistant Epithelial Ovarian Cancer · Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Stanford Health Care | Palo Alto, California, United States | — |
| Ocala Oncology | Ocala, Florida, United States | — |
| NYU Langone Hospital-Long Island | Mineola, New York, United States | — |
| NYU Langone: Laura and Isaac Perlmutter Cancer Center | New York, New York, United States | — |
| CHUM - Centre hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | — |
| PanOncology Trials | San Juan, Puerto Rico | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05243524